Details for New Drug Application (NDA): 050578
✉ Email this page to a colleague
NDA 050578 describes FORTAZ, which is a drug marketed by Pai Holdings Pharm and is included in two NDAs. Additional details are available on the FORTAZ profile page.
The generic ingredient in FORTAZ is ceftazidime sodium. There are seventeen drug master file entries for this compound. Additional details are available on the ceftazidime sodium profile page.
The generic ingredient in FORTAZ is ceftazidime sodium. There are seventeen drug master file entries for this compound. Additional details are available on the ceftazidime sodium profile page.
Summary for 050578
| Tradename: | FORTAZ |
| Applicant: | Pai Holdings Pharm |
| Ingredient: | ceftazidime |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050578
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jul 19, 1985 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jul 19, 1985 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jul 19, 1985 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
